Description
Methylisoindigotin is an indirubin derivative that displays anti-inflammatory, anti-angiogenic, and anticancer chemotherapeutic activities. In vitro, methylisoindigotin inhibits growth and proliferation of various leukemia cell lines. In LPS-stimulated macrophages and keratinocytes, methylisoindigotin decreases production of NO and pro-inflammatory cytokines. This compound also induces apoptosis and inhibits tumor growth in animal models of colon adenocarcinoma. In other models, methylisoindigotin decreases GSK expression and downregulates Wnt activity. Additionally, methylisoindigotin decreases production of VEGF and suppresses tube formation in vitro.
References
Huang M, Lin HS, Lee YS, et al. Evaluation of meisoindigo, an indirubin derivative: in vitro antileukemic activity and in vivo pharmacokinetics. Int J Oncol. 2014 Oct;45(4):1724-34. PMID: 25050545.
Zhang HJ, Zhang Y, Jin J, et al. Mechanism about therapeutic effect of meisoindigo on psoriasis via down-regulation of the TLR4-TAK-NF-kappaB pathways. Yao Xue Xue Bao. 2013 Apr;48(4):503-7. PMID: 23833936.
Zuo MX, Li Y, Zhou JH, et al. Effect of Meisoindigo on Wnt signal pathway in K562 and HL-60 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Jun;18(3):579-82. PMID: 20561405.
Mingxin Z, Yan L, Hongbo W, et al. The antitumor activity of meisoindigo against human colorectal cancer HT-29 cells in vitro and in vivo. J Chemother. 2008 Dec;20(6):728-33. PMID: 19129071.
Xiao Z, Wang Y, Lu L, et al. Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro. Leuk Res. 2006 Jan;30(1):54-9. PMID: 15982734.
